IMPAX Laboratories, Inc. today announced that Arthur A. Koch, Jr., its senior vice president and chief financial officer, will provide a review of the information contained in the Company’s Form 10 Registration Statement, including a review of the Company’s GAAP to non-GAAP method of revenue recognition at a meeting with analysts on Monday, November 17th, at 9:00 a.m. Eastern time.
Individuals may listen to the live or an archived presentation made at the event, which will be posted in the investor relations section of the Company’s web site at www.impaxlabs.com. To listen to the live presentation, please go to the web site 15 minutes prior to its start to register, download, and install the necessary audio software. This presentation will be archived on the Company’s web site for 30 days.
About IMPAX Laboratories, Inc.
IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and markets its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.
Contacts:
IMPAX
Laboratories, Inc.
Larry Hsu, Ph.D. President & CEO
510-476-2000,
Ext. 1111
Arthur A. Koch, Jr., Sr. VP & CFO
215-933-0351
Mark
Donohue, Sr. Director IR
215-933-3526
www.impaxlabs.com
or
Investor
Relations Contacts:
Lippert/Heilshorn
& Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce
Voss, 310-691-7100
bvoss@lhai.com
www.lhai.com
